← All companies
$2.25
+3.21% (+$0.07) on the day
Close Nov 13, 2026
Market cap
$12.9M
1 month
−29.47%
52-week range
$1.90–$6.40
Last month
Why we cover it
A licensed manufacturer of pharmaceutical-grade psilocybin and MDMA with real revenue, which we called the clearest "real, small and actually growing" story among small psychedelic stocks. Also listed on the CSE as OPTI.
Financials
Recent financials aren't available in a standard format for this company. See its SEC filings ↗
In the Journal (4)
- Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
- Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
- Sep 17, 2026 The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
- Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.